TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.67M | -22.98M | -35.71M | -36.95M | -34.13M |
| Total Depreciation and Amortization | 693.00K | 723.00K | 767.00K | 698.00K | 678.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.59M | 2.07M | 2.84M | 2.60M | 2.25M |
| Change in Net Operating Assets | 1.11M | -11.82M | -359.00K | 386.00K | -6.38M |
| Cash from Operations | -24.28M | -32.00M | -32.46M | -33.27M | -37.59M |
| Capital Expenditure | -70.00K | -171.00K | -1.43M | -1.28M | -1.53M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 15.00M | 34.00M | 49.72M | 15.06M |
| Cash from Investing | -70.00K | 14.83M | 32.58M | 48.44M | 13.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 73.00K | 0.00 | 191.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -75.00K | -525.00K |
| Cash from Financing | -- | 73.00K | 0.00 | 116.00K | -525.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.35M | -17.10M | 112.00K | 15.29M | -24.58M |